What does ZELLIK PHARMA do?

ZELLIK PHARMA is a pharmacy in Asse. Private Limited, started on 16 June 2006, 1 establishment.

What is the address of ZELLIK PHARMA?

The registered office of ZELLIK PHARMA is located at Brusselsesteenweg 812, 1731 Asse.

Is ZELLIK PHARMA still active?

Yes. According to the CBE (30 October 2026) ZELLIK PHARMA is active, legal situation “Normale toestand”, started on 16 June 2006.

Is ZELLIK PHARMA registered on Peppol?

Yes, ZELLIK PHARMA is registered on the Peppol network with ID 0208:0881910538.

What is the enterprise number of ZELLIK PHARMA?

The enterprise number of ZELLIK PHARMA is BE0881910538.

When was ZELLIK PHARMA founded?

ZELLIK PHARMA was founded on 16 June 2006.

Who are the directors of ZELLIK PHARMA?

According to the 2025 annual accounts, the directors of ZELLIK PHARMA are: Pharma Force NV.

Is ZELLIK PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 June 2006; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did ZELLIK PHARMA make in 2025?

ZELLIK PHARMA posted a profit after taxes of € 389 in financial year 2025.

What is the revenue of ZELLIK PHARMA?

As a small company, ZELLIK PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 336,913.

How much does an employee at ZELLIK PHARMA earn?

The average wage cost per full-time employee at ZELLIK PHARMA was € 70,000 in 2025: staff costs of € 308,034 for 4.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ZELLIK PHARMA have?

According to the 2025 annual accounts, ZELLIK PHARMA has 4.4 full-time equivalents (FTE).

ZELLIK PHARMA (Private Limited) - Asse - BE0881910538

Dossier ZELLIK PHARMA, printed on 30 October 2026 from databakkes.be/en/0881910538/zellik-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 9.4 to 4.4.

Financials

Financial year 2025

ZELLIK PHARMA from Asse, company number BE0881910538, closed financial year 2025 with a result of € 389 after tax. For that financial year ZELLIK PHARMA recorded a gross margin of € 336,913 and equity of € 442,955. Compared with financial year 2024, the result moved from € -93,373 to € 389. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 23, 2026.

What it is worth Growing

€ 442,955

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 389

▲ still € 93,373 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 413

▼ 97% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 428,755.

People and assets in 2025

Full-time equivalents

4.4

▼ 4.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 308,034

▼ 32% vs 2024

€ 70,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 9,047

▼ 71% vs 2024

Of which on lease € 611.

Debts at end 2025

Bank debt

€ 13,448

▼ 66% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 114,007

▼ 34% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 48,804

▼ 36% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 3,434,270 Revenue 2022: € 3,434,270 First fiscal year in the series	-	-	-
Gross margin	€ 599,255 Gross margin 2022: € 599,255 First fiscal year in the series	€ 622,656 Gross margin 2023: € 622,656 ▲ 4% vs 2022 (€ 599,255) Favourable step	€ 393,644 Gross margin 2024: € 393,644 ▼ 37% vs 2023 (€ 622,656) Unfavourable step	€ 336,913 Gross margin 2025: € 336,913 ▼ 14% vs 2024 (€ 393,644) Unfavourable step	▼ 14%
Profit after taxes	€ 110,430 Profit after taxes 2022: € 110,430 First fiscal year in the series	€ 68,565 Profit after taxes 2023: € 68,565 ▼ 38% vs 2022 (€ 110,430) Unfavourable step	€ -93,373 Profit after taxes 2024: € -93,373 ▼ € 161,938 vs 2023 (€ 68,565) Unfavourable step	€ 389 Profit after taxes 2025: € 389 ▲ € 93,762 vs 2024 (€ -93,373) Favourable step	▲ € 93,762
Equity	€ 467,374 Equity 2022: € 467,374 First fiscal year in the series	€ 535,939 Equity 2023: € 535,939 ▲ 15% vs 2022 (€ 467,374) Favourable step	€ 442,566 Equity 2024: € 442,566 ▼ 17% vs 2023 (€ 535,939) Unfavourable step	€ 442,955 Equity 2025: € 442,955 Unchanged (€ 442,566) Favourable step
Total debts	€ 717,202 Total debts 2022: € 717,202 First fiscal year in the series	€ 580,119 Total debts 2023: € 580,119 ▼ 19% vs 2022 (€ 717,202) Favourable step	€ 728,019 Total debts 2024: € 728,019 ▲ 25% vs 2023 (€ 580,119) Unfavourable step	€ 807,372 Total debts 2025: € 807,372 ▲ 11% vs 2024 (€ 728,019) Unfavourable step	▲ 11%
Cash	€ 2,946 Cash 2022: € 2,946 First fiscal year in the series	€ 5,258 Cash 2023: € 5,258 ▲ 78% vs 2022 (€ 2,946) Favourable step	€ 12,087 Cash 2024: € 12,087 ▲ 130% vs 2023 (€ 5,258) Favourable step	€ 413 Cash 2025: € 413 ▼ 97% vs 2024 (€ 12,087) Unfavourable step	▼ 97%
Retained profit	€ 453,174 Retained profit 2022: € 453,174 First fiscal year in the series	€ 521,739 Retained profit 2023: € 521,739 ▲ 15% vs 2022 (€ 453,174) Favourable step	€ 428,366 Retained profit 2024: € 428,366 ▼ 18% vs 2023 (€ 521,739) Unfavourable step	€ 428,755 Retained profit 2025: € 428,755 Unchanged (€ 428,366) Favourable step
Bank debt	€ 63,917 Bank debt 2022: € 63,917 First fiscal year in the series	€ 64,562 Bank debt 2023: € 64,562 ▲ 1% vs 2022 (€ 63,917) Unfavourable step	€ 39,262 Bank debt 2024: € 39,262 ▼ 39% vs 2023 (€ 64,562) Favourable step	€ 13,448 Bank debt 2025: € 13,448 ▼ 66% vs 2024 (€ 39,262) Favourable step	▼ 66%
Balance sheet total	€ 1,184,576 Balance sheet total 2022: € 1,184,576 First fiscal year in the series	€ 1,116,059 Balance sheet total 2023: € 1,116,059 ▼ 6% vs 2022 (€ 1,184,576) Unchanged	€ 1,170,585 Balance sheet total 2024: € 1,170,585 ▲ 5% vs 2023 (€ 1,116,059) Unchanged	€ 1,250,328 Balance sheet total 2025: € 1,250,328 ▲ 7% vs 2024 (€ 1,170,585) Unchanged	▲ 7%
Employees (FTE)	8.6 Employees (FTE) 2022: 8.6 First fiscal year in the series	9.4 Employees (FTE) 2023: 9.4 ▲ 0.8 vs 2022 (8.6) Unchanged	8.9 Employees (FTE) 2024: 8.9 ▼ 0.5 vs 2023 (9.4) Unchanged	4.4 Employees (FTE) 2025: 4.4 ▼ 4.5 vs 2024 (8.9) Unchanged	▼ 4.5

Key figures of ZELLIK PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ZELLIK PHARMA?

What happened at ZELLIK PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 23, 2026 New annual accounts for financial year 2025: profit of € 389. filed late Source: NBB ↗
2018 Pharma Force NV became a director. NBB
Jun 16, 2006 Start of the company according to the CBE. KBO
Jun 10, 2006 New establishment in Dilbeek. KBO

In short

From € 110,430 profit in 2022 to € 389 profit in 2025.

Paid € 74,026 in corporate taxes since 2022.

Best year ever: 2022, with € 110,430 profit.

On average € 76,600 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

peeters mathieu management 100%

The stake of peeters mathieu management comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

ZELLIK PHARMA

Behind ZELLIK PHARMA is Pharma Force NV. The shares are held by peeters mathieu management (100%).

Directors

According to the 2025 annual accounts

Pharma Force NV

Director · represented by Mathieu Peeters

Also active at: Pharma2Care, PHARMA BASE

since 2018

Shareholders

peeters mathieu management

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Brusselsesteenweg 812

1731 Asse

2.156.122.532

Elzenstraat 4

1702 Dilbeek

Active since 10 June 2006

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0881.910.538

VAT number

BE 0881.910.538

Registered office

Brusselsesteenweg 812, 1731 Asse

Names & denominations

ZELLIK PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

16 June 2006

Peppol

Active · Active since 13 Jun 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

ZELLIK PHARMA

Warning lights

Financials

What happened to ZELLIK PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions